Table 1.
Patient clinical and microbiological characteristics
| Variables | Dalbavancin (n = 12) | SOC (n = 263) | p value |
|---|---|---|---|
| Age, years (mean ± SD) | 41.75 ± 6.3 | 41.71 ± 11.6 | 0.986 |
| Sex, male | 12 (100) | 159 (60.5) | 0.006 |
| Race | |||
| Caucasian | 11 (91.7) | 163 (62) | 0.061 |
| African American | 1 (8.3) | 92 (35) | < 0.001 |
| Pacific Islander or unknown origin | 0 (0) | 8 (3) | 1.000 |
| ICD-10 | |||
| Cellulitis (L03.XXX) | 9 (75) | 177 (67.3) | 0.757 |
| Abscess (L02.XXX) | 3 (25) | 79 (30) | 0.002 |
| Postop wound infections (T81.XXX) | 0 (0) | 7 (2.7) | 1.000 |
| Antibiotic allergies | |||
| Total | 1 (8.3) | 65 (24.7) | 0.305 |
| Penicillin | 0 (0) | 30 (11.4) | 0.374 |
| Sulfonamide | 1 (8.3) | 17 (6.5) | 0.564 |
| Clindamycin | 0 (0) | 5 (1.9) | 1.000 |
| Vancomycin | 0 (0) | 5 (1.9) | 1.000 |
| Other | 0 (0) | 8 (3.0) | 1.000 |
| Vitals | |||
| BMI, kg/m2 | 29.15 [26.9–38.7] | 28.89 [23.5–35.4] | 0.555 |
| Initial BMI ≥ 30 kg/m2 | 4 (33.3) | 109 (41.4) | 0.766 |
| Maximum temperature in 24 h, °F | 98.85 [98.5–99.8] | 98.9 [98.5–100.1] | 0.761 |
| Maximum temperature in 24 h, > 100.4 °F | 2 (16.7) | 65 (24.7) | 0.736 |
| ≥ 2 (RR ≥ 22, SBP ≤ 100) | 0 (0) | 1 (0.38) | 1.000 |
| Maximum WBC in 24 h, cells/mm3 | 11.15 [9.4–15.3] | 10.90 [8.7–15.1] | 0.722 |
| Maximum WBC in 24 h ≥ 12 cells/mm3 | 4 (33.3) | 114 (43.4) | 0.564 |
| Comorbidities | |||
| Diabetes | 2 (16.7) | 53 (20.2) | 1.000 |
| Hypertension | 3 (25) | 73 (27.8) | 1.000 |
| Hyperlipidemia | 3 (25) | 13 (4.9) | 0.026 |
| Cancer | 2 (16.7) | 5 (1.9) | 0.033 |
| Venous thromboembolism | 2 (16.7) | 10 (3.8) | 0.090 |
| Peripheral artery disease | 1 (8.3) | 0 (0) | 0.044 |
| Chronic kidney disease | 0 (0) | 4 (1.5) | 1.000 |
| Hepatitis | 1 (8.3) | 13 (4.9) | 0.473 |
| Cirrhosis | 0 (0) | 3 (1.1) | 1.000 |
| ABSSSI history documented | 4 (33.3) | 59 (22.4) | 0.480 |
| History of Clostridioides difficile | 1 (8.3) | 3 (1.1) | 0.164 |
| IVDU | 3 (25) | 36 (13.7) | 0.387 |
| Recreation drug abuse (non-IV) | 3 (25) | 59 (22.4) | 0.736 |
| Smoker | 8 (66.7) | 144 (54.8) | 0.557 |
| ID consult | 10 (37) | 126 (47.9) | 0.019 |
| Microbiological data | |||
| Cultures obtained | 12 (100) | 234 (89) | 0.622 |
| Wound culture | 8 (30.8) | 148 (29.7) | 0.562 |
| Abscess culture | 4 (15.4) | 105 (21.1) | 0.769 |
| Blood culture | 10 (38.5) | 189 (38) | 0.521 |
| Urine culture | 4 (15.38) | 56 (11.24) | 0.301 |
| Positive culture | 7 (58.3) | 128 (54.7) | 0.566 |
| S. aureus infection | 7 (100) | 75 (58.6) | 0.047 |
| MRSA | 4 (57.1) | 39 (52) | 0.100 |
| MSSA | 3 (42.9) | 35 (46.7) | 0.221 |
| Blood culture | 0 (0) | 21 (9) | 0.608 |
| Wound culture | 7 (58.3) | 120 (51.3) | 0.556 |
| Urine culture | 0 (0) | 11 (4.7) | 1.000 |
| Inpatient antibiotics | |||
| Vancomycin | 12 (100) | 215 (81.7) | 0.135 |
| Piperacillin/tazobactam | 6 (50) | 162 (61.6) | 0.547 |
| Meropenem | 0 (0) | 1 (0.4) | 1.000 |
| Cefazolin | 4 (33.3) | 41 (15.6) | 0.114 |
| Clindamycin (IV/PO) | 3 (25) | 143 (54.4) | 0.073 |
| Other | 3 (25) | 102 (38.8) | 0.545 |
Data are presented as n (%) or median [IQR] unless otherwise indicated
BMI body mass index, RR respiratory rate, SBP systolic blood pressure, IVDU intravenous drug users, ID infectious diseases, MRSA methicillin-resistant S. aureus, MSSA methicillin-susceptible S. aureus, PO oral